Bristol-Myers Squibb Co  

(Public, NYSE:BMY)   Watch this stock  
Find more results for bmy
56.03
0.00 (0.00%)
Pre-market: 55.69 -0.34 (-0.61%)
Dec 7, 8:43AM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 49.03 - 77.12
Open     -
Vol / Avg. 1,100.00/11.75M
Mkt cap 94.45B
P/E 27.91
Div/yield 0.38/2.71
EPS 2.01
Shares 1.67B
Beta 0.94
Inst. own 70%
Jan 26, 2017
Q4 2016 Bristol-Myers Squibb Co Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 7, 2016
Bristol-Myers Squibb Co at Citi Global Healthcare Conference
Nov 16, 2016
Bristol-Myers Squibb Co at Stifel Healthcare Conference - Webcast
Nov 8, 2016
Bristol-Myers Squibb Co at Credit Suisse Healthcare Conference
Oct 27, 2016
Q3 2016 Bristol-Myers Squibb Co Earnings Call - Webcast
Oct 27, 2016
Q3 2016 Bristol-Myers Squibb Co Earnings Release
Oct 9, 2016
Bristol-Myers Squibb Co Conference Call to Discuss ESMO 2016 - Webcast
Sep 29, 2016
Bristol-Myers Squibb Co at Leerink Partners Rare Disease & IO Roundtable Series - Webcast
Sep 27, 2016
Nektar Therapeutics Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb - Webcast
Sep 14, 2016
Bristol-Myers Squibb Co at Bank of America Merrill Lynch Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 24.69% 9.85%
Operating margin 31.55% 8.57%
EBITD margin - 16.27%
Return on average assets 14.64% 4.98%
Return on average equity 31.58% 10.75%
Employees 25,000 -
CDP Score - 100 C

Address

345 PARK AVE
NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

Officers and directors

Giovanni Caforio M.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Charles A. Bancroft Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Louis S. Schmukler President - Global Manufacturing and Supply
Age: 60
Bio & Compensation  - Reuters
Francis M. Cuss Executive Vice President, Chief Scientific Officer
Age: 61
Bio & Compensation  - Reuters
Sandra Leung Executive Vice President, General Counsel and Corporate Secretary
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Murdo Gordon Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Paul von Autenried Senior Vice President - Enterprise Services, Chief Information Officer
Age: 54
Bio & Compensation  - Reuters
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 55
Bio & Compensation  - Reuters
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ann Powell Judge Senior Vice President - Global Human Resources
Age: 50
Bio & Compensation  - Reuters